The coming problem of HIV-associated Alzheimer's disease

Medical Hypotheses

Volumn 69, Issue 5, 2007, Pages 1140-1143

  Alisky, Joseph Martin ^a  

^a MARSHFIELD CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; GLYCOPROTEIN GP 120; TRANSACTIVATOR PROTEIN;

AGING; ALZHEIMER DISEASE; ARTICLE; BRAIN ATROPHY; BRAIN TISSUE; DISEASE ASSOCIATION; DISEASE COURSE; EXCITOTOXICITY; GERIATRIC PATIENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; LIPODYSTROPHY; NEUROFIBRILLARY TANGLE; NEUROLOGIC EXAMINATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SENILE PLAQUE; SURVIVAL TIME;

ALZHEIMER DISEASE; COMORBIDITY; DISEASE OUTBREAKS; FORECASTING; HIV INFECTIONS; HUMANS; INCIDENCE; RISK ASSESSMENT; RISK FACTORS;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 34548705864     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2007.02.030     Document Type: Article

References (35)

1. Brew B.J., Pemberton L., Blennow K., Wallin A., and Hagberg L. CSF amyloid beta42 and tau levels correlate with AIDS dementia complex. Neurology 65 9 (2005) 1490-1492
2. Alzheimer A. Über eine eigenartige erkrankung der hirnrinde [About a peculiar disease of the cerebral cortex.] [article in German]. Allgemeine Zeitschrift für Psychiatrie und psychisch-gerichtliche Medizin 64 (1907) 146-148 English translation in: Arch Neurol 1967; 21:109-10
3. Cysique L.A., Maruff P., Darby D., and Brew B.J. The assessment of cognitive function in advanced HIV-1 infection and AIDS dementia complex using a new computerised cognitive test battery. Arch Clin Neuropsychol 21 2 (2006) 185-194
4. Sadek J.R., Johnson S.A., White D.A., Salmon D.P., et al. Retrograde amnesia in dementia: comparison of HIV-associated dementia, Alzheimer's disease, and Huntington's disease. Neuropsychology 18 4 (2004) 692-699
5. Chang L., Lee P.L., Yiannoutsos C.T., Ernst T., et al. A multicenter in vivo proton-MRS study of HIV-associated dementia and its relationship to age. Neuroimage 23 4 (2004) 1336-1347
6. Mott R.T., and Hulette C.M. Neuropathology of Alzheimer's disease. Neuroimaging Clin N Am 15 4 (2005) 755-765
7. Robertson K.R., Robertson W.T., Ford S., et al. Highly active antiretroviral therapy improves neurocognitive functioning. J Acq Immun Def Synd 36 1 (2004) 562-566
8. Valcour V., Shikuma C.M., Watters M.R., et al. Cognitive impairment in older HIV-1 seropositive individuals: prevalence and potential mechanisms. AIDS 18 Suppl. 1 (2004) S79-S86
9. Brew B.J. Evidence for a change in AIDS dementia complex in the era of highly active antiretroviral therapy and the possibility of new forms of AIDS dementia complex. AIDS 18 Suppl. 1 (2004) S75-S78
10. Weiler P.G. Risk factors associated with senile dementia of the Alzheimer's type. Am J Prev Med 2 5 (1986) 297-305
11. Borjesson-Hanson A., Edin E., Gislason T., and Skoog I. The prevalence of dementia in 95 year olds. Neurology 63 12 (2004) 2436-2438
12. Stoll M., and Schmidt R.E. Immune restoration inflammatory syndromes: apparently paradoxical clinical events after the initiation of HAART. Curr HIV/AIDS Rep 1 3 (2004) 122-127
13. Stoll M., and Schmidt R.E. Immune restoration inflammatory syndromes: the dark side of successful antiretroviral treatment. Curr Infect Dis Rep 5 3 (2003) 266-276
14. Gray F., Bazille C., and Adle-Biassette H. Central nervous system immune reconstitution disease in acquired immunodeficiency syndrome patients receiving highly active antiretroviral treatment. J Neurovirol 11 Suppl. 3 (2005) 16-22
15. Sastre M., Klockgether T., and Heneka M.T. Contribution of inflammatory processes to Alzheimer's disease: molecular mechanisms. Int J Dev Neurosci 24 2-3 (2006) 167-176
16. Barbaro G. Metabolic and cardiovascular complications of highly active antiretroviral therapy for HIV infection. Curr HIV Res 4 1 (2006) 79-85
17. Luchsinger J.A., Reitz C., Honig L.S., Tang M.X., et al. Aggregation of vascular risk factors and risk of incident Alzheimer disease. Neurology 65 4 (2005) 545-551
18. Newman A.B., Fitzpatrick A.L., Lopez O., et al. Dementia and Alzheimer's disease incidence in relationship to cardiovascular disease in the cardiovascular health study cohort. J Am Geriatr Soc 53 7 (2005) 1101-1107
19. Nebuloni M., Pellegrinelli A., Ferri A., et al. Beta amyloid precursor protein and patterns of HIV p24 immunohistochemistry in different brain areas of AIDS patients. AIDS 15 5 (2001) 571-575
20. Rostasy K., Egles C., Chauhan A., et al. SDF-1alpha is expressed in astrocytes and neurons in the AIDS dementia complex: an in vivo and in vitro study. J Neuropathol Exp Neurol 62 6 (2003) 617-626
21. D'Aversa T.G., Eugenin E.A., and Berman J.W. NeuroAIDS: contributions of the human immunodeficiency virus-1 proteins Tat and gp120 as well as CD40 to microglial activation. J Neurosci Res 81 3 (2005) 436-446
22. Starkstein S.E., and Jorge R. Dementia after traumatic brain injury. Int Psychogeriatr 17 Suppl. 1 (2005) S93-S107
23. Honig L.S., Tang M.X., Albert S., Costa R., et al. Stroke and the risk of Alzheimer disease. Arch Neurol 60 12 (2003) 1707-1712
24. Mattson M.P. Infectious agents and age-related neurodegenerative disorders. Ageing Res Rev 3 1 (2004) 105-120
25. Tositti G., Rassu M., Fabris P., et al. Chlamydia pneumoniae infection in HIV-positive patients: prevalence and relationship with lipid profile. HIV Med 6 1 (2005) 27-32
26. Jordano Q., Falco V., Almirante B., et al. Invasive pneumococcal disease in patients infected with HIV: still a threat in the era of highly active antiretroviral therapy. Clin Infect Dis 38 11 (2004) 1623-1628
27. Podell M., March P.A., Buck W.R., and Mathes L.E. The feline model of neuroAIDS: understanding the progression towards AIDS dementia. J Psychopharmacol 14 3 (2000) 205-213
28. Williams K., Westmoreland S., Greco J., et al. Magnetic resonance spectroscopy reveals that activated monocytes contribute to neuronal injury in SIV neuroAIDS. J Clin Invest 115 9 (2005) 2534-2545
29. Gauthier S.G. Alzheimer's disease: the benefits of early treatment. Eur J Neurol 12 Suppl. 3 (2005) 11-16
30. Doraiswamy P.M., and Xiong G.L. Pharmacological strategies for the prevention of Alzheimer's disease. Expert Opin Pharmacother 7 1 (2006) 1-10
31. van Wijk J.P., de Koning E.J., Cabezas M.C., et al. Comparison of rosiglitazone and metformin for treating HIV lipodystrophy: a randomized trial. Ann Intern Med 143 5 (2005) 337-346
32. Prasithsirikul W., and Bunnag P. Improvement of fat redistribution, insulin resistance and hepatic fatty infiltration in HIV-associated lipodystrophy syndrome by pioglitazone: a case report. J Med Assoc Thailand 87 2 (2004) 166-172
33. Calmy A., Hirschel B., Hans D., Karsegard V.L., and Meier C.A. Glitazones in lipodystrophy syndrome induced by highly active antiretroviral therapy. AIDS 17 5 (2003) 770-772
34. Calza L., Manfredi R., and Chiodo F. Hyperlipidaemia in patients with HIV-1 infection receiving highly active antiretroviral therapy: epidemiology, pathogenesis, clinical course and management. Int J Antimicrob Agents 22 2 (2003) 89-99
35. Sacktor N., Schifitto G., and McDermott M.P. Transdermal selegiline in HIV-associated cognitive impairment: pilot, placebo-controlled study. Neurology 54 1 (2000) 233-235